Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
- DOI
- 10.1002/ajh.27539
- Published
- 2025-01-22
- Container
- American Journal of Hematology
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1002/ajh.27539,
title = {Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study},
author = {Nichola Cooper and A. J. Gerard Jansen and Robert Bird and Jiří Mayer and Michelle Sholzberg and Michael D. Tarantino and Mamta Garg and Paula F. Ypma and Vickie McDonald and Charles Percy and Milan Košťál and Isaac Goncalves and Lachezar H. Bogdanov and Terry B. Gernsheimer and Remco Diab and Mengjie Yao and Ahmed Daak and David J. Kuter},
year = {2025},
journal = {American Journal of Hematology},
doi = {10.1002/ajh.27539},
url = {https://doi.org/10.1002/ajh.27539}
}RIS
TY - JOUR TI - Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study AU - Nichola Cooper AU - A. J. Gerard Jansen AU - Robert Bird AU - Jiří Mayer AU - Michelle Sholzberg AU - Michael D. Tarantino AU - Mamta Garg AU - Paula F. Ypma AU - Vickie McDonald AU - Charles Percy AU - Milan Košťál AU - Isaac Goncalves AU - Lachezar H. Bogdanov AU - Terry B. Gernsheimer AU - Remco Diab AU - Mengjie Yao AU - Ahmed Daak AU - David J. Kuter PY - 2025 JO - American Journal of Hematology DO - 10.1002/ajh.27539 UR - https://doi.org/10.1002/ajh.27539 ER -
APA
Cooper, N., Jansen, A. J. G., Bird, R., Mayer, J., Sholzberg, M., Tarantino, M. D., Garg, M., Ypma, P. F., McDonald, V., Percy, C., Košťál, M., Goncalves, I., Bogdanov, L. H., Gernsheimer, T. B., Diab, R., Yao, M., Daak, A., & Kuter, D. J. (2025). Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study. American Journal of Hematology. https://doi.org/10.1002/ajh.27539
Source records
- crossref · retrieved 2026-09-26T01:13:58.565Z